VALN Valneva SE
Price Chart
Executive Summary
Valneva announced participation in investor conferences (Jefferies, Oddo BHF, BNP Paribas) and a travel medicine conference, with key discussion topics including its commercial vaccines and the Lyme disease candidate LB6V (partnered with Pfizer, which reported positive Phase 3 results and plans regulatory submissions). This is a routine update with no material financial or operational data.
Actionable Insight
Monitor updates from Pfizer regarding regulatory submissions for LB6V (Lyme vaccine), which could be a significant catalyst if accepted by regulators. The conferences may provide additional color on pipeline progress, but no near-term stock-moving news is expected from this filing alone.
Key Facts
- Valneva to present and hold investor meetings at Jefferies Global Healthcare Conference (June 3), Oddo BHF Nextcap Forum (June 12), and BNP Paribas SMID Cap Conference (June 24).
- LB6V (Lyme disease vaccine candidate) partnered with Pfizer; Pfizer reported positive Phase 3 results and plans regulatory submissions.
- Valneva will be a Gold Sponsor at the 10th Northern European Conference on Travel Medicine (June 3-5).
- No financial figures or guidance were disclosed in the filing.
Financial Impact
No financial impact disclosed; event is a routine conference participation announcement.
Risk Factors
- Regulatory submissions for LB6V may face delays or unfavorable outcomes.
- Commercial vaccine sales may underperform expectations.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-039308 |
| Document: a6-kcoverpagetemplate.htm | 0001628280-26-039308 |
| Document: 0001628280-26-039308-index-headers.html | 0001628280-26-039308 |
| Document: 0001628280-26-039308-index.html | 0001628280-26-039308 |
| Document: 0001628280-26-039308.txt | 0001628280-26-039308 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
1d ago
|
6-K
| — | awaiting T+1 | — | — |
|
Jun 1, 2026
5d ago
|
6-K
| $5.95 $5.63 | ▼ −5.38% | ▼ −5.52% | $5.48 (−7.90%) |
|
May 5, 2026
4w ago
|
6-K
| $5.29 $5.41 | ▲ +2.27% | ▲ +0.88% | $5.48 (+3.59%) |
|
Mar 26, 2026
10w ago
|
6-K
| $6.32 $6.17 | ▼ −2.37% | ▼ −0.69% | $5.48 (−13.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access